Publication date: Oct 31, 2024
Nanoparticles, defined as particles ranging from 1 to 100 nanometers in size, are revolutionizing the approach to combating bacterial infections amid a backdrop of escalating antibiotic resistance. Bacterial infections remain a formidable global health challenge, causing millions of deaths annually and encompassing a spectrum from common illnesses like Strep throat to severe diseases such as tuberculosis and pneumonia. The misuse of antibiotics has precipitated the rise of resistant strains like methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Mycobacterium tuberculosis (MDR-TB), and carbapenem-resistant Enterobacteriaceae (CRE), underscoring the critical need for innovative therapeutic strategies. Nanotechnology offers a promising avenue in this crisis. Nanoparticles possess unique physical and chemical properties that distinguish them from traditional antibiotics. Their high surface area to volume ratio, ability to be functionalized with various molecules, and distinctive optical, electronic, and magnetic characteristics enable them to exert potent antibacterial effects. Mechanisms include physical disruption of bacterial membranes, generation of Reactive Oxygen Species (ROS), and release of metal ions that disrupt bacterial metabolism. Moreover, nanoparticles penetrate biofilms and bacterial cell walls more effectively than conventional antibiotics and can be precisely targeted to minimize off-target effects. Crucially, nanoparticles mitigate the development of bacterial resistance by leveraging multiple simultaneous mechanisms of action, which make it challenging for bacteria to adapt through single genetic mutations. As research advances, nanotechnology holds immense promise in transforming antibacterial treatments, offering effective solutions that address current infections and combat antibiotic resistance globally. This review provides a comprehensive overview of nanoparticle applications in antibacterial therapies, highlighting their mechanisms, advantages over antibiotics, and future directions in healthcare innovation.
Concepts | Keywords |
---|---|
Annually | antibacterial |
Challenging | antibiotic resistance |
Mycobacterium | bacterial infections |
Nanotechnology | Nanoparticles |
Pneumonia | nanotechnology |
therapeutic agents. |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Bacterial Infections |
disease | IDO | antibiotic resistance |
disease | MESH | tuberculosis |
pathway | KEGG | Tuberculosis |
disease | MESH | pneumonia |
drug | DRUGBANK | Meticillin |
pathway | REACTOME | Release |
pathway | REACTOME | Metabolism |
disease | IDO | cell |
disease | IDO | bacteria |
disease | MESH | infections |